

## NEISSERIA MENINGITIDIS A, C, W-135, X, Y SEROGROUPS

### Technology Summary

*Neisseria meningitidis* consists of 13 serogroups that cause meningococcal disease. The serogroups A, B, C, W, X, and Y cause the most disease worldwide and the serogroups B, C, and Y cause the most disease in the United States. FDA researchers have isolated multiple strains of *neisseria meningitidis* as potential candidates for vaccine development including the X serotype.

- *Neisseria meningitidis* X strain M8210 (E-2013-017)
- *Neisseria meningitidis* Y strain S1975 (E-2013-018)
- *Neisseria meningitidis* A strain M1027 (E-2013-019)
- *Neisseria meningitidis* C strain C11 (E-2013-020)
- *Neisseria meningitidis* W-135 strain S877 (E-2013-021)

### Potential Commercial Applications

- Research tool
- Vaccine and diagnostic development

### Competitive Advantages

- *Neisseria meningitidis* serogroup X characterization

**Development Stage:** Research Materials

**Inventors:** Willie Vann, Che-Hung Lee

### Publications:

- Muindi, KM., et. al. Characterization of the meningococcal serogroup X capsule N-acetylglucosamine-1-phosphotransferase. *Glycobiology*. 2014 Feb;24(2):139-49. PMID: [24134880](#)
- Gudlavalleti, SK., et. al. Comparison of *Neisseria meningitidis* serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide. *Vaccine*. 2007 Nov 14;25(46):7972-80. PMID: [17936445](#)

**Product Area:** Research materials, vaccine, diagnostic

**FDA Reference No:** E-2013-017, E-2013-018, E-2013-019, E-2013-020, E-2013-021

### Licensing Contact:

Ken Millburne, J.D.

FDA Technology Transfer Program

Email: [FDALicensing@fda.hhs.gov](mailto:FDALicensing@fda.hhs.gov)

Phone: 240-402-2245